Swiss biotechnology company Windward Bio Group has priced its initial public offering at $17 per share, raising $175 million at the midpoint of its proposed $16 to $18 price range. The offering consisted of approximately 10.3 million shares. The company also secured an additional $50 million through a concurrent private placement of shares and pre-funded warrants to Sanofi, bringing the total capital raised through the transactions to approximately $225 million.

Based in Basel, Switzerland, Windward Bio is developing ultra-long-acting antibody treatments for respiratory and dermatologic diseases, with clinical programs targeting asthma, chronic obstructive pulmonary disease (COPD), and atopic dermatitis.

IPO and Private Placement Details

Windward Bio sold approximately 10.3 million shares at $17 each, raising $175 million in gross proceeds. The pricing represents the midpoint of the initially proposed range.

Alongside the public offering, Sanofi participated in a $50 million private placement involving shares and pre-funded warrants. The additional investment provides another source of capital as Windward advances its clinical development programs.

The company will trade on the Nasdaq under the ticker symbol WWB. Jefferies, TD Securities, Piper Sandler, and UBS Investment Bank acted as joint bookrunners for the offering.

WIN378 Leads the Clinical Pipeline

Windward Bio’s lead candidate, WIN378, is an ultra-long-acting antibody targeting thymic stromal lymphopoietin (TSLP), a target also addressed by Tezspire. The candidate is designed to offer twice-yearly dosing, compared with Tezspire’s dosing schedule of once every four weeks.

WIN378 is being evaluated in a Phase 2/3 trial for severe uncontrolled asthma and a Phase 2 trial for COPD. The company expects to report Phase 2 asthma results in the first half of 2027.

The development program reflects Windward’s focus on antibody treatments intended to reduce dosing frequency while addressing chronic respiratory conditions.

Second Candidate WIN027 Advances Toward Phase 2

The company’s second program, WIN027, is a bispecific antibody targeting both TSLP and interleukin-13 (IL-13). It is currently in Phase 1 development.

Windward plans to begin enrolling patients in Phase 2 trials for COPD and atopic dermatitis during the first half of 2027. These studies would expand the company’s clinical pipeline into additional respiratory and dermatologic indications.

Windward in-licensed WIN378 from Kelun-Biotech and Harbour BioMed, while WIN027 was in-licensed from Qyuns Therapeutics.

Closing Insights

Windward Bio’s $175 million IPO, combined with its $50 million private placement from Sanofi, provides approximately $225 million in new capital to support its antibody development programs. The company’s near-term clinical milestones include expected Phase 2 asthma results for WIN378 in the first half of 2027 and the planned start of Phase 2 enrollment for WIN027 across COPD and atopic dermatitis.

As Windward enters the public market, investor attention is likely to focus on clinical progress, the potential advantages of less frequent dosing, and the development of its two antibody candidates across multiple disease areas.